A Phase 3 interventional study of IPX066 and IR CD-LD in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 73 sites in 8 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 6th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2009.
This study's enrollment of 471 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
A randomized, double-blind, active-control, parallel-group 13-week comparison of IPX066 versus regular carbidopa-levodopa (CD-LD). Prior to randomization, subjects on a stable regular LD regimen will enter a 3-week dose-adjustment period for IR CD-LD, followed by a 6-week dose-conversion period to IPX066.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently being treated with IR LD (CD-LD or benserazide-LD) and on a stable regimen of IR LD for at least 4 weeks and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
Drug: IPX066 · Drug: IR CD-LD
Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
Drug: IPX066 · Drug: IR CD-LD
extended-release carbidopa-levodopa capsules
Also known as: ER CD-LD
immediate-release carbidopa-levodopa tablets
Also known as: immediate-release carbidopa-levodopa
Percentage of "Off" Time During Waking Hours at End of Study
Percentage of "off" time during waking hours at end of study is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."
Time frame: 22 weeks
"Off" Time
"Off" time hours is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."
Time frame: 22 weeks
"On" Time Without Troublesome Dyskinesia
"On" time without troublesome dyskinesiais measured by using the Parkinson's disease diary. "On" time without troublesome dyskinesia describes a period when the participant experiences decreased Parkinsonian symptoms (e.g. immobility or inability to move with ease) without dyskinesia (i.e. difficulty in performing voluntary movements) that affect daily living."
Time frame: 22 weeks
Study period was form September 29, 2009 to January 19, 2011.
| Milestone | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| Started | 0 | 471 |
| Completed | 0 | 450 |
| Not completed | 0 | 21 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Noncompliance with study drug | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 7 |
| Withdrew: Various | 0 | 9 |
| Milestone | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| Started | 450 | 0 |
| Completed | 393 | 0 |
| Not completed | 57 | 0 |
| Withdrew: Adverse event | 23 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 13 | 0 |
| Withdrew: Withdrawal by subject | 12 | 0 |
| Withdrew: Various | 3 | 0 |
| Withdrew: Protocol violation | 4 | 0 |
| Milestone | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| Started | 201 | 192 |
| Completed | 186 | 182 |
| Not completed | 15 | 10 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Noncompliance with study drug | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Various | 4 | 0 |
Percentage of "off" time during waking hours at end of study is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."
| percentage | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| Percentage of "Off" Time During Waking Hours at End of Study | 23.82 ± 14.91 | 29.79 ± 15.81 |
"Off" time hours is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."
| hours | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| "Off" Time | 3.87 ± 2.46 | 4.88 ± 2.71 |
"On" time without troublesome dyskinesiais measured by using the Parkinson's disease diary. "On" time without troublesome dyskinesia describes a period when the participant experiences decreased Parkinsonian symptoms (e.g. immobility or inability to move with ease) without dyskinesia (i.e. difficulty in performing voluntary movements) that affect daily living."
| hours | IPX066 | IR CD-LD (Active Comparator) |
|---|---|---|
| "On" Time Without Troublesome Dyskinesia | 11.84 ± 2.96 | 10.91 ± 2.82 |
Collected over 22 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPX066 | — | 11/201 (5.5%) | 57/201 (28.4%) |
| Carbidopa-Levodopa | — | 5/192 (2.6%) | 50/192 (26%) |
| Event | IPX066 | Carbidopa-Levodopa |
|---|---|---|
| Atrial FibrillationCardiac disorders | 0/201 | 1/192 |
| Chest PainGeneral disorders | 0/201 | 1/192 |
| OsteomyelitisInfections and infestations | 0/201 | 1/192 |
| PneumoniaInfections and infestations | 0/201 | 1/192 |
| Subdural HematomaInjury, poisoning and procedural complications | 0/201 | 1/192 |
| Intervertebral Disc DegenerationMusculoskeletal and connective tissue disorders | 0/201 | 1/192 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/201 | 1/192 |
| Toe AmputationSurgical and medical procedures | 0/201 | 1/192 |
| Acute Myocardial InfarctionCardiac disorders | 1/201 | 0/192 |
| Small Intestinal ObstructionGastrointestinal disorders | 1/201 | 0/192 |
| Event | IPX066 | Carbidopa-Levodopa |
|---|---|---|
| InsomniaPsychiatric disorders | 7/201 | 2/192 |
| nauseaGastrointestinal disorders | 6/201 | 3/192 |
| FallInjury, poisoning and procedural complications | 6/201 | 4/192 |
| DepressionPsychiatric disorders | 1/201 | 5/192 |
| DizzinessNervous system disorders | 5/201 | 2/192 |
| DyskinesiaNervous system disorders | 5/201 | 2/192 |
| Oedema PeripheralGeneral disorders | 4/201 | 4/192 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/201 | 4/192 |
| Urinary Tract InfectionInfections and infestations | 4/201 | 4/192 |
| Sleep DisorderPsychiatric disorders | 4/201 | 4/192 |
All treated
| Age, Continuous(years) | IPX066 | Carbidopa-Levodopa | Total |
|---|---|---|---|
| Mean | 63.1 ± 10.0 | 63.4 ± 8.8 | 63.2 ± 9.4 |
| Sex: Female, Male(Participants) | IPX066 | Carbidopa-Levodopa | Total |
|---|---|---|---|
| Female | 72 | 67 | 139 |
| Male | 129 | 125 | 254 |
| Ethnicity (NIH/OMB)(Participants) | IPX066 | Carbidopa-Levodopa | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 8 | 11 |
| Not Hispanic or Latino | 192 | 182 | 374 |
| Unknown or Not Reported | 6 | 2 | 8 |
| Race/Ethnicity, Customized(participants) | IPX066 | Carbidopa-Levodopa | Total |
|---|---|---|---|
| White | 196 | 186 | 382 |
| Black or African American | 2 | 1 | 3 |
| Asian | 1 | 1 | 2 |
| American Indian or Alaskan Native | 0 | 2 | 2 |
| Other | 1 | 2 | 3 |
| Unknown | 1 | 0 | 1 |
| Region of Enrollment(participants) | IPX066 | Carbidopa-Levodopa | Total |
|---|---|---|---|
| Canada | 10 | 8 | 18 |
| Romania | 3 | 4 | 7 |
| United States | 98 | 93 | 191 |
| Ukraine | 37 | 38 | 75 |
| Poland | 34 | 33 | 67 |
| France | 2 | 1 | 3 |
| Germany | 12 | 11 | 23 |
| Spain | 5 | 4 | 9 |
Plan to share: No
The record gives a start of Sep 2009, a primary completion of Jan 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 5 years after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.